What is the Purpose of this Study?
Primary Objective 1.1.1 To examine the efficacy of computerized cognitive training (BrainHQ) compared to the attention control on perceived cognitive impairment post intervention (12 weeks post-randomization) as measured by the FACT-Cog PCI scale. 1.2 Secondary Objectives 1.2.1 To examine the efficacy of computerized cognitive training (BrainHQ) compared to the attention control in maintaining improved FACT-Cog PCI scores over time. 1.2.2 To examine the efficacy of computerized cognitive training (BrainHQ) compared to the attention control in improving objectively measured cognitive performance (neuropsychological tests of memory, attention and working memory, speed of processing and executive function) over time. 1.2.3 To examine the efficacy of computerized cognitive training (BrainHQ) compared to attention control on self-reported cognitive function over time as measured by the FACT-Cog total
Eligibility
- * The participant must provide study-specific informed consent prior to any study specific procedures and authorization permitting release of personal health information.
- * The participant must have a first time diagnosis of non-metastatic breast cancer which is Stage I-III.
- * The participant must have a score of less than 12 on the PROMIS Adult v2.0 - Cognitive Function 4a.
- * Participants with greater than or equal to 6 months to 5 years post-treatment (completion of initial surgery +/- adjuvant chemotherapy/radiation therapy) except may still be taking endocrine therapy or HER2-directed adjuvant therapy.
Where can I participate?
CS Cancer at Cedars-Sinai Medical Center : Ana Martin
More about this Clinical Trial
What is the full name of this clinical trial?
NRG-CC011: Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial